IOL Chemicals and Pharmaceuticals Limited

rs,

Complex, Bandra (E) Mumbai - 400 051 Security Symbol: IOLCP BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400 001 Security Code: 524164 Subject: Investor Presentation – Q2 & H1 FY24

35%

017 Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share Spread over a sprawling campus of over 170 acres Key Highlights Largest producer

30%

a Zero Discharge Effluent Treatment Plant 2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share Customer base across 80 countries Over 20 products are commercialized with 8 produc

12.9%

-FY24 Performance Q2FY24 Financial Performance 552.41 Revenues (Rs. cr) 71.21 EBITDA (Rs. cr) 12.9% EBITDA Margin 37.79 Profit After Tax (Rs. cr) 6.8% PAT Margin • • • EBITDA margins surge 54

6.8%

Revenues (Rs. cr) 71.21 EBITDA (Rs. cr) 12.9% EBITDA Margin 37.79 Profit After Tax (Rs. cr) 6.8% PAT Margin • • • EBITDA margins surge 54% despite flattish revenue growth on lower raw materia

54%

9% EBITDA Margin 37.79 Profit After Tax (Rs. cr) 6.8% PAT Margin • • • EBITDA margins surge 54% despite flattish revenue growth on lower raw material costs Robust 15.8% growth in pharma revenue

15.8%

• • EBITDA margins surge 54% despite flattish revenue growth on lower raw material costs Robust 15.8% growth in pharma revenue Chemical segment revenue declines 5.7% • • • Reduction in raw material

5.7%

on lower raw material costs Robust 15.8% growth in pharma revenue Chemical segment revenue declines 5.7% • • • Reduction in raw material cost YoY leads to better EBITDA and Net Profit margins Pharma

10%

in raw material cost YoY leads to better EBITDA and Net Profit margins Pharma revenue grows nearly 10% leading to overall sales growth Chemical revenue flattish in second quarter H1-FY24 Financial Per

13.5%

second quarter H1-FY24 Financial Performance 1122.65 Revenues (Rs. cr) 151.13 EBITDA (Rs. cr) 13.5% EBITDA Margin 84.00 Profit After Tax (Rs. cr) 7.5% PAT Margin 5 Geographical and Segmental h

7.5%

evenues (Rs. cr) 151.13 EBITDA (Rs. cr) 13.5% EBITDA Margin 84.00 Profit After Tax (Rs. cr) 7.5% PAT Margin 5 Geographical and Segmental highlights Chemical Segment (Rs. crore) Pharma Segment

6.7%

2 12.9% 15.7 4.4 51.1 51.1 13.3 37.8 6.8% -0.5 37.3 6.4 541.4 5.1 546.5 509.7 36.7 6.7% 11.32 3.51 21.90 21.90 6.23 15.67 2.9% -0.3 15.3 2.7 YoY 0.7% 1.1% 93.5% 620bps 132

Regulatory Filings

4

Investor Relations Advisors

1

Regulatory Filings

US/EU/ANVISA (Antidiabetic and potential antineoplastic used for patients with type 2 diabetes) Dedicated manufacturing block with an installed capacity of 7,200 MT/Annum

Regulatory Filings

US/EU/ENVISA Paracetamol Lamotrigine Clopidogrel Bisulphate Metformin Hydrochloride Pantoprazole Sodium (Antiplatelet drug, used in cardiovascular therapies, preventing future heart attacks, strokes, and other clot-related diseases) Dedicated manufacturing facility with installed capacity of 240 MT/Annum, with a fully backward integrated process.

Regulatory Filings

US/EU/ENVISA/China ( Treatment for gastroesophageal reflux disease and promote healing of tissue damage caused by gastric acid) Fully backward integration process, commercialized with an installed capacity >200 MT/Annum

Investor Relations Advisors

IOL Chemicals & Pharmaceuticals Ltd. Adfactorspr Pvt. Ltd. Mr. Pardeep Kumar Khanna, CFO pardeepkhanna@iolcp.com Darshan Mankad darshan.mankad@adfactorspr.com www.iolcp.com Hanishi Shah hanishi.shah@adfactorspr.com www.adfactorspr.com